Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Change in Intangibles (2022 - 2024)

Historic Change in Intangibles for Eton Pharmaceuticals (ETON) over the last 3 years, with Q4 2024 value amounting to $8.1 million.

  • Eton Pharmaceuticals' Change in Intangibles rose 94774.19% to $8.1 million in Q4 2024 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 20722.66%. This contributed to the annual value of $10.0 million for FY2024, which is 118877.42% up from last year.
  • As of Q4 2024, Eton Pharmaceuticals' Change in Intangibles stood at $8.1 million, which was up 94774.19% from $1.9 million recorded in Q1 2024.
  • In the past 5 years, Eton Pharmaceuticals' Change in Intangibles registered a high of $8.1 million during Q4 2024, and its lowest value of $775000.0 during Q4 2023.
  • Over the past 3 years, Eton Pharmaceuticals' median Change in Intangibles value was $1.9 million (recorded in 2022), while the average stood at $3.2 million.
  • Examining YoY changes over the last 5 years, Eton Pharmaceuticals' Change in Intangibles showed a top increase of 94774.19% in 2024 and a maximum decrease of 94774.19% in 2024.
  • Quarter analysis of 3 years shows Eton Pharmaceuticals' Change in Intangibles stood at $2.0 million in 2022, then tumbled by 61.25% to $775000.0 in 2023, then surged by 947.74% to $8.1 million in 2024.
  • Its Change in Intangibles stands at $8.1 million for Q4 2024, versus $1.9 million for Q1 2024 and $775000.0 for Q4 2023.